Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943173 · ClinicalTrials.gov registry record · Early Phase 1
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
A Early Phase 1 study of Stage III Ovarian Cancer AJCC v8 and BRCA1 Gene Mutation, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03943173: Active Early Phase 1 study of Stage III Ovarian Cancer AJCC v8 and BRCA1 Gene Mutation, sponsored by M.D. Anderson Cancer Center.
NCT03943173 is a Early Phase 1 study of Stage III Ovarian Cancer AJCC v8 and BRCA1 Gene Mutation that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants, below the 127-participant average among 9 other Stage III Ovarian Cancer AJCC v8 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03943173, a Early Phase 1 study of Stage III Ovarian Cancer AJCC v8 and BRCA1 Gene Mutation, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial studies how well olaparib works in treating patients with newly diagnosed BRCA-mutant ovarian, primary peritoneal, or fallopian cancer before surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Feasibility defined by number of subjects who are able to receive two cycles of PARP inhibition without unacceptable toxicity or disease progression (new disease or increase of CA125 from baseline \> 50%). Will be analyzed using descriptive statistics. Will be estimated using a 90% credible interval
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG Chemotherapy
- PROCEDURE Therapeutic Conventional Surgery
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-06-07 |
| Est. Completion | 2027-06-27 |
| Phase | Early Phase 1 |
What the registry record for NCT03943173 still lists
NCT03943173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 127-participant average among 9 other Stage III Ovarian Cancer AJCC v8 trials with a reported enrollment target (88% lower).
The record links to 10 conditions, with Stage III Ovarian Cancer AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Olaparib is the first listed.
NCT03943173 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03943173 about?
NCT03943173 is a clinical study titled "Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery". This early phase I trial studies how well olaparib works in treating patients with newly diagnosed BRCA-mutant ovarian, primary peritoneal, or fallopian cancer before surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT03943173?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2019-06-07. Estimated completion is 2027-06-27.
What conditions does trial NCT03943173 study?
This clinical trial studies the following conditions: Stage III Ovarian Cancer AJCC v8, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Primary Peritoneal High Grade Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma.
What interventions are being tested in trial NCT03943173?
The interventions under investigation include: Olaparib (DRUG), Chemotherapy (DRUG), Therapeutic Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT03943173?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03943173 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Ovarian Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03943173's enrollment target sits among peer trials
15 10th of 9 the lowest of 9 other Stage III Ovarian Cancer AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage III Ovarian Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
RECRUITING · Early Phase 1
-
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
RECRUITING · Early Phase 1
-
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
RECRUITING
-
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
RECRUITING · NA
-
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
RECRUITING · Phase 2
-
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI